evitria company logo
    • Recombinant Ab Production Service
    • Afucosylated Ab Service
    • Fc-silenced Ab Service
    • Bispecific Ab Production Service
    • HTP Production Service
    • Other Protein Production Service
  • Products
    • STR – True Fc Silencing Technology
    • GlymaxX® – Glycoengineering and ADCC Enhancement
    • Opti-mAb® – scFv Stabilization
    Our Technologies
    • About Evitria
    • Events
    • Partnerships
    • FAQs
    • Contact
  • Features

    • Transient Antibody Production
    • CHO cells – first choice for antibody production
    • Antibody reformatting and engineering
    • Scalability & Reproducibility

    Antibodies

    • Recombinant Antibodies
    • Afucosylated antibodies
    • Fc-silenced antibodies
    • Bispecific/multispecific antibodies

    Resources

    • Blog
    • Encyclopedia
    • Publications
Contact
  • Expression Services

    Recombinant Ab Production Service

    Afucosylated Ab Service

    Fc-silenced Ab Service

    Bispecific Ab Production Service

    Hight-Throughput Ab Production Service

    Other Protein Production

  • Products
  • Our Technologies

      Our Technologies

      STR – True Fc Silencing Technology

      GlymaxX® – Glycoengineering and ADCC Enhancement

      Opti-mAb® scFv Stabilization

      Our Technologies
  • About us

      About us

      About Evitria

      Events

      Partnerships

      FAQs

      Contact

  • Antibody Journal

      Antibody Journal

      Features

      Transient Antibody Production

      CHO cells – first choice for antibody production

      Antibody reformatting and engineering

      Scalability & Reproducibility

      Antibodies

      Recombinant Antibodies

      Afucosylated antibodies

      Fc-silenced antibodies

      Bispecific/multispecific antibodies

      Resources

      Blog

      Encyclopedia

      Publications

Let’s get in contact
  • LinkedIn
  • YouTube
  1. evitria
  2. 2025

2025

  • Afucosylated antibodies
  • Antibodies
  • Antibodies Journal
  • Bispecific antibodies
  • CHO Cells
  • High-Throughput
  • Monoclonal antibodies
  • News
  • Recombinant antibodies
  • Therapy Development

  • Paratope mapping of tilvestamab, an anti-AXL function-blocking antibody, using high-throughput bacterial expression of secreted scFv-osmY fusion proteins

    Anja Avatar
    June 11, 2026
  • Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody–drug conjugate

    technik Avatar
    December 14, 2025
  • A blocking antibody against anti-Müllerian hormone restores ovulation and normal androgen levels in a spontaneous rat model of polycystic ovary syndrome

    technik Avatar
    December 14, 2025
  • Broadening the Therapeutic Window of ADCs Using Site-Specific Bioconjugation Showcased by an MMAE-Containing Peptide Linker in a CD79b-Targeting ADC

    technik Avatar
    December 14, 2025
  • The Arming of Natural Killer Cells With Fc‐Engineered Monoclonal Antibodies Confers Specificity Against Tumor B Cells

    technik Avatar
    December 14, 2025
  • Progastrin Promotes Colorectal Cancer Stem Cell‐Like Properties via the Receptor PZR

    technik Avatar
    December 14, 2025
  • Functional avidity of anti-B7H3 CAR-T constructs predicts antigen density thresholds for triggering effector function

    technik Avatar
    December 14, 2025
  • ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in mice

    technik Avatar
    December 14, 2025
  • Macrophage-Engaging IgG4 Antibody Triggers Cytotoxicity against Integrin αvβ3+ Cancers

    technik Avatar
    December 14, 2025
  • Evaluation of Antibody–Drug Conjugate Performances Using a Novel HPLC–DAD Method for Tumor-Specific Detection of DM4 and S -Methyl-DM4

    technik Avatar
    December 14, 2025
  • Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation

    technik Avatar
    December 14, 2025
  • Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2 + 1 TCBs

    technik Avatar
    December 14, 2025
1 2
Next Page→

4 weeks from sequence to recombinant antibody.

  • LinkedIn
  • YouTube
  • Privacy Policy
  • About Evitria
  • HTML Sitemap

©2026 evitria ag

PowerEd by

We Value Your Privacy

This website uses cookies to enhance your browsing experience and provide personalized services. We require your consent to set these cookies on your device. Please note that we also use cookies from US companies that have not signed up to the EU-US data protection agreement.

Your Privacy

This site uses tracking technologies. You may opt in or opt out of the use of these technologies.

Marketing cookies and services are used to deliver personalized advertisements, promotions, and offers. These technologies enable targeted advertising and marketing campaigns by collecting information about users' interests, preferences, and online activities.

Analytics cookies and services are used for collecting statistical information about how visitors interact with website. These technologies provide insights into website usage, visitor behavior, and site performance to understand and improve the site and enhance user experience.

Personalization cookies enable the website to remember your choices and provide enhanced, more personal features. These cookies may track your preferences and show you relevant content based on your browsing patterns.

Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedback, and other third-party features.

Essential cookies are necessary for the website to function properly. These cookies ensure basic functionalities and security features of the website.